Clearside Biomedical, Inc.(CLSD)Earnings, Financials & Key Ratios
CLSD•NASDAQ
$0.41
$2M mkt cap·Price updated May 1, 2026
AboutClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Show more
- Revenue$2M-79.8%
- EBITDA-$29M-15.7%
- Net Income-$34M-5.7%
- EPS (Diluted)-7.05+11.3%
- Gross Margin91.05%-4.8%
- EBITDA Margin-1722.12%-471.7%
- Operating Margin-1735.7%-474.7%
- Net Margin-2064.42%-422.8%
- Interest Coverage-2.95-11.3%
CLSD Key Insights
Clearside Biomedical, Inc. (CLSD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Sales declining 5.2% over 5 years
- ✗Shares diluted 19.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLSD Price & Volume
Clearside Biomedical, Inc. (CLSD) stock price & volume — 10-year historical chart
Loading chart...
CLSD Growth Metrics
Clearside Biomedical, Inc. (CLSD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-5.2%
3 Years-61.68%
TTM-56.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.94%
Return on Capital
10 Years-111.15%
5 Years-81.36%
3 Years-87.37%
Last Year-121.51%
CLSD Peer Comparison
Clearside Biomedical, Inc. (CLSD) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 2.12B | 9.68 | -6.82 | -18.67% | -5.58% | -64.55% | 0.12 | |
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 REPL | 265.97M | 3.34 | -1.09 | -149.55% | 0.18 | |||
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 AGIO | 1.64B | 27.53 | -3.87 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ALDX | 104.08M | 1.73 | -1.84 | -87.71% | 0.22 |
Compare CLSD vs Peers
Clearside Biomedical, Inc. (CLSD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLSD Income Statement
Clearside Biomedical, Inc. (CLSD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 520K | 345K | 30K | 2.17M | 7.89M | 29.57M | 1.33M | 8.23M | 1.66M | 3.33M |
| Revenue Growth % | - | -33.65% | -91.3% | 7143.33% | 263.28% | 274.65% | -95.51% | 519.89% | -79.77% | -56.78% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 204K | 355K | 149K | 481K |
| COGS % of Revenue | - | - | - | - | - | - | 15.37% | 4.32% | 8.95% | - |
| Gross Profit | 520K▲ 0% | 345K▼ 33.7% | 30K▼ 91.3% | 2.17M▲ 7143.3% | 7.89M▲ 263.3% | 29.57M▲ 274.7% | 1.12M▼ 96.2% | 7.87M▲ 600.9% | 1.51M▼ 80.8% | 2.85M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 84.63% | 95.68% | 91.05% | 85.55% |
| Gross Profit Growth % | 1675.76% | -33.65% | -91.3% | 7143.33% | 263.28% | 274.65% | -96.2% | 600.89% | -80.75% | - |
| Operating Expenses | 25.72M | 58.75M | 82.97M | 32.48M | 25.83M | 30.2M | 31.4M | 32.72M | 30.4M | 25.81M |
| OpEx % of Revenue | 4945.77% | 17029.86% | 276583.33% | 1494.57% | 327.2% | 102.12% | 2366.24% | 397.7% | 1826.74% | - |
| Selling, General & Admin | 6.26M | 9.7M | 14.68M | 16.82M | 10.76M | 11.66M | 11.77M | 11.87M | 11.81M | 12.67M |
| SG&A % of Revenue | 1204.42% | 2811.59% | 48946.67% | 774% | 136.26% | 39.44% | 886.96% | 144.29% | 709.56% | - |
| Research & Development | 19.45M | 49.05M | 68.29M | 15.66M | 15.07M | 18.54M | 19.63M | 20.85M | 18.59M | 13.22M |
| R&D % of Revenue | 3741.35% | 14218.26% | 227636.67% | 720.57% | 190.94% | 62.68% | 1479.28% | 253.42% | 1117.19% | - |
| Other Operating Expenses | 0 | -567K | 127K | 0 | 0 | 0 | 0 | 0 | 0 | -84K |
| Operating Income | -25.2M▲ 0% | -58.41M▼ 131.8% | -82.94M▼ 42.0% | -30.3M▲ 63.5% | -17.93M▲ 40.8% | -627K▲ 96.5% | -30.28M▼ 4728.9% | -24.84M▲ 17.9% | -28.88M▼ 16.3% | -22.96M▲ 0% |
| Operating Margin % | -4845.77% | -16929.86% | -276483.33% | -1394.57% | -227.2% | -2.12% | -2281.61% | -302.02% | -1735.7% | -689.76% |
| Operating Income Growth % | -45.51% | -131.8% | -42.01% | 63.46% | 40.82% | 96.5% | -4728.87% | 17.94% | -16.25% | - |
| EBITDA | -25.13M | -58.23M | -82.76M | -30.09M | -17.75M | -449K | -30.13M | -24.78M | -28.66M | -22.63M |
| EBITDA Margin % | -4833.27% | -16877.1% | -275853.33% | -1384.86% | -224.92% | -1.52% | -2270.69% | -301.2% | -1722.12% | -679.78% |
| EBITDA Growth % | -45.64% | -131.67% | -42.13% | 63.64% | 41% | 97.47% | -6610.91% | 17.77% | -15.66% | 7.56% |
| D&A (Non-Cash Add-back) | 65K | 182K | 189K | 211K | 180K | 178K | 145K | 67K | 226K | 332K |
| EBIT | -25.2M | -58.41M | -82.94M | -30.3M | -17.88M | 376K | -29.61M | -23.13M | -24.57M | -14.7M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | -2.67M | -7.64M | -8.32M | -9.88M |
| Interest Income | 0 | 0 | 0 | 1.03M | 335K | 0 | 669K | 1.72M | 1.46M | 701K |
| Interest Expense | 0 | 0 | 0 | 1.03M | 335K | 0 | 3.34M | 9.36M | 9.78M | 10.58M |
| Other Income/Expense | -684K | -567K | 127K | -466K | -275K | 1M | -2.67M | -7.64M | -5.47M | -2.32M |
| Pretax Income | -25.88M▲ 0% | -58.98M▼ 127.9% | -82.82M▼ 40.4% | -30.77M▲ 62.8% | -18.21M▲ 40.8% | 376K▲ 102.1% | -32.95M▼ 8862.5% | -32.48M▲ 1.4% | -34.35M▼ 5.7% | -25.28M▲ 0% |
| Pretax Margin % | -4977.31% | -17094.2% | -276060% | -1416.01% | -230.68% | 1.27% | -2482.82% | -394.91% | -2064.42% | -759.42% |
| Income Tax | -65K | -182K | 127K | 0 | 0 | 0 | 0 | 0 | 0 | 715K |
| Effective Tax Rate % | 0.25% | 0.31% | -0.15% | 0% | 0% | 0% | 0% | 0% | 0% | -2.83% |
| Net Income | -25.88M▲ 0% | -58.98M▼ 127.9% | -82.82M▼ 40.4% | -30.77M▲ 62.8% | -18.21M▲ 40.8% | 376K▲ 102.1% | -32.95M▼ 8862.5% | -32.48M▲ 1.4% | -34.35M▼ 5.7% | -26M▲ 0% |
| Net Margin % | -4977.31% | -17094.2% | -276060% | -1416.01% | -230.68% | 1.27% | -2482.82% | -394.91% | -2064.42% | -780.9% |
| Net Income Growth % | -46.73% | -127.86% | -40.43% | 62.85% | 40.82% | 102.06% | -8862.5% | 1.4% | -5.75% | 18.45% |
| Net Income (Continuing) | -25.88M | -58.98M | -82.82M | -30.77M | -18.21M | 376K | -32.95M | -32.48M | -34.35M | -26M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -29.55▲ 0% | -34.95▼ 18.3% | -40.35▼ 15.5% | -12.00▲ 70.3% | -5.85▲ 51.3% | 0.09▲ 101.6% | -8.25▼ 8830.2% | -7.95▲ 3.6% | -7.05▲ 11.3% | -4.97▲ 0% |
| EPS Growth % | -36.81% | -18.27% | -15.45% | 70.26% | 51.25% | 101.62% | -8830.16% | 3.64% | 11.32% | 23.94% |
| EPS (Basic) | -29.55 | -34.95 | -40.35 | -12.00 | -5.85 | 0.10 | -8.25 | -7.95 | -7.05 | - |
| Diluted Shares Outstanding | 874.07K | 1.69M | 2.05M | 2.54M | 3.1M | 3.99M | 4.01M | 4.12M | 4.92M | 5.23M |
| Basic Shares Outstanding | 874.07K | 1.69M | 2.05M | 2.54M | 3.1M | 3.9M | 4.01M | 4.12M | 4.92M | 5.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLSD Balance Sheet
Clearside Biomedical, Inc. (CLSD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 83.63M | 37.64M | 42.94M | 25.22M | 18.12M | 42.14M | 49.4M | 30.12M | 21.27M | 8.25M |
| Cash & Short-Term Investments | 83.63M | 37.64M | 40.88M | 22.59M | 17.29M | 30.44M | 48.42M | 28.92M | 20.02M | 6.8M |
| Cash Only | 34.82M | 9.22M | 8.04M | 22.59M | 17.29M | 30.44M | 48.42M | 28.92M | 20.02M | 6.8M |
| Short-Term Investments | 48.81M | 28.42M | 32.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 10M | 0 | 170K | 507K | 266K |
| Days Sales Outstanding | - | - | - | - | - | 123.42 | - | 7.54 | 111.21 | 85.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 921K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 290K | 116K | 17K | 1.49M | 109K | 779K | 279K | 311K | 13K | 0 |
| Total Non-Current Assets | 360K | 360K | 1.18M | 1.56M | 1.2M | 767K | 1.9M | 3.89M | 3.85M | 3.39M |
| Property, Plant & Equipment | 94K | 885K | 790K | 1.2M | 944K | 607K | 1.87M | 3.87M | 3.82M | 3.36M |
| Fixed Asset Turnover | 5.53x | 0.39x | 0.04x | 1.82x | 8.36x | 48.72x | 0.71x | 2.13x | 0.44x | 0.93x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 360K | 360K | 360K | 0 | 260K | 0 | 30K | 0 | 0 | 0 |
| Other Non-Current Assets | -94K | -885K | 26K | 360K | 0 | 160K | 0 | 30K | 30K | 120K |
| Total Assets | 84.81M▲ 0% | 40.49M▼ 52.3% | 44.12M▲ 9.0% | 26.78M▼ 39.3% | 19.32M▼ 27.8% | 42.9M▲ 122.0% | 51.3M▲ 19.6% | 34.02M▼ 33.7% | 25.13M▼ 26.1% | 11.64M▲ 0% |
| Asset Turnover | 0.01x | 0.01x | 0.00x | 0.08x | 0.41x | 0.69x | 0.03x | 0.24x | 0.07x | 0.19x |
| Asset Growth % | 302.82% | -52.26% | 8.96% | -39.31% | -27.84% | 122.04% | 19.58% | -33.69% | -26.14% | -192.04% |
| Total Current Liabilities | 5.41M | 13.52M | 10.48M | 10.9M | 9.94M | 4.64M | 5.78M | 6.81M | 4.79M | 2.77M |
| Accounts Payable | 2.59M | 5.38M | 6.87M | 1.28M | 2M | 941K | 1.05M | 2.21M | 1.45M | 796K |
| Days Payables Outstanding | - | - | - | - | - | - | 1.88K | 2.27K | 3.56K | 1K |
| Short-Term Debt | 0 | 3.2M | 556K | 1.33M | 991K | 0 | 349K | 364K | 0 | 0 |
| Deferred Revenue (Current) | 160K | 140K | 0 | 5M | 5M | 0 | 205K | 75K | 0 | 0 |
| Other Current Liabilities | 23K | 219K | 1.86M | 2.28M | 1.13M | 0 | 2.34M | 2.31M | 0 | 0 |
| Current Ratio | 15.46x | 2.78x | 4.10x | 2.31x | 1.82x | 9.08x | 8.54x | 4.42x | 4.44x | 4.44x |
| Quick Ratio | 15.46x | 2.78x | 4.10x | 2.31x | 1.82x | 8.88x | 8.54x | 4.42x | 4.44x | 4.44x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -918.04 |
| Total Non-Current Liabilities | 7.59M | 8.01M | 10.02M | 4.72M | 616K | 288K | 34.91M | 43.12M | 59.19M | 62.82M |
| Long-Term Debt | 7.59M | 4.81M | 9.42M | 3.82M | 0 | 0 | 33.98M | 41.99M | 51.77M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 897K | 616K | 288K | 936K | 649K | 328K | 783K |
| Deferred Tax Liabilities | -320K | -750K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 610K | 605K | 0 | 0 | 0 | 0 | 480K | 7.09M | 137.6M |
| Total Liabilities | 13.15M | 19.08M | 20.5M | 15.62M | 10.56M | 4.93M | 40.7M | 49.93M | 63.98M | 65.59M |
| Total Debt | 7.59M | 8.01M | 9.97M | 6.41M | 1.98M | 675K | 35.26M | 43M | 52.47M | 446K |
| Net Debt | -27.24M | -1.22M | 1.93M | -16.19M | -15.31M | -29.76M | -13.16M | 14.08M | 32.45M | -6.36M |
| Debt / Equity | 0.11x | 0.37x | 0.42x | 0.57x | 0.23x | 0.02x | 3.32x | - | - | -0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.28x |
| Interest Coverage | - | - | - | -29.31x | -53.54x | - | -9.07x | -2.65x | -2.95x | -1.39x |
| Total Equity | 71.66M▲ 0% | 21.41M▼ 70.1% | 23.62M▲ 10.3% | 11.16M▼ 52.8% | 8.76M▼ 21.5% | 37.98M▲ 333.4% | 10.61M▼ 72.1% | -15.91M▼ 250.0% | -38.85M▼ 144.2% | -53.95M▲ 0% |
| Equity Growth % | 295.47% | -70.12% | 10.3% | -52.76% | -21.46% | 333.36% | -72.07% | -250.01% | -144.19% | -382.06% |
| Book Value per Share | 81.98 | 12.69 | 11.53 | 4.38 | 2.83 | 9.51 | 2.64 | -3.86 | -7.90 | -10.31 |
| Total Shareholders' Equity | 71.66M | 21.41M | 23.62M | 11.16M | 8.76M | 37.98M | 10.61M | -15.91M | -38.85M | -53.95M |
| Common Stock | 25K | 25K | 32K | 44K | 52K | 60K | 61K | 63K | 77K | 78K |
| Retained Earnings | -65.25M | -124.22M | -206.89M | -237.66M | -255.87M | -255.49M | -288.44M | -320.92M | -355.27M | -373.96M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -13K | -8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLSD Cash Flow Statement
Clearside Biomedical, Inc. (CLSD) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -22.71M | -51.08M | -79.2M | -27.07M | -13.12M | -10.73M | -13.37M | -18.14M | -24.7M | -24.7M |
| Operating CF Margin % | -4367.12% | -14806.67% | -264000% | -1245.65% | -166.2% | -36.29% | -1007.16% | -220.46% | -1484.25% | - |
| Operating CF Growth % | -63.35% | -124.95% | -55.04% | 65.82% | 51.53% | 18.19% | -24.52% | -35.69% | -36.19% | -1111.61% |
| Net Income | -25.88M | -58.98M | -82.82M | -30.77M | -18.21M | 376K | -32.95M | -32.48M | -34.35M | -26M |
| Depreciation & Amortization | 65K | 182K | 189K | 211K | 180K | 178K | 145K | 67K | 226K | 332K |
| Stock-Based Compensation | 1.31M | 3.36M | 4.79M | 4.61M | 3.6M | 5.05M | 4.88M | 4.2M | 4.51M | 3.33M |
| Deferred Taxes | 65K | 181K | -748K | -52K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 439K | 211K | 266K | 230K | 188K | -998K | 3.32M | 9.36M | 6.59M | 2.97M |
| Working Capital Changes | 1.29M | 3.95M | -874K | -1.3M | 1.12M | -15.34M | 11.24M | 720K | -1.68M | -1.92M |
| Change in Receivables | 0 | 0 | 0 | 0 | 1.89M | -10.87M | 10.42M | -220K | -51K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -681K | 0 | 0 | 0 | 0 |
| Change in Payables | 1.42M | 4.71M | -314K | -5.58M | 0 | 681K | 694K | 614K | -1.43M | -2.34M |
| Cash from Investing | -49.14M | 20.12M | -3.76M | 32.92M | -55K | 0 | -246K | -1.78M | -638K | 9.3M |
| Capital Expenditures | -3K | -306K | -88K | -25K | -55K | 0 | -246K | -1.78M | -977K | -453K |
| CapEx % of Revenue | 0.58% | 88.7% | 293.33% | 1.15% | 0.7% | - | 18.54% | 21.6% | 58.71% | - |
| Acquisitions | 0 | -20.12M | -660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -360K | 20.12M | 660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 86.39M | 5.36M | 81.78M | 8.7M | 7.87M | 23.78M | 31.33M | 414K | 16.44M | 4.91M |
| Debt Issued (Net) | 1.53M | 0 | 1.7M | -5M | -4.35M | 0 | 30.64M | 0 | 0 | 961K |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 695K | 1000K | 1000K | 2M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 31K | 305K | 515K | 52K | 258K | 499K | 0 | -1.25M | 47K | 418K |
| Net Change in Cash | 14.54M▲ 0% | -25.6M▼ 276.1% | -1.18M▲ 95.4% | 14.55M▲ 1332.2% | -5.31M▼ 136.5% | 13.05M▲ 345.8% | 17.88M▲ 37.0% | -19.5M▼ 209.0% | -8.9M▲ 54.4% | -7.09M▲ 0% |
| Free Cash Flow | -22.71M▲ 0% | -51.39M▼ 126.3% | -79.29M▼ 54.3% | -27.09M▲ 65.8% | -13.18M▲ 51.4% | -10.73M▲ 18.5% | -13.61M▼ 26.8% | -19.91M▼ 46.3% | -25.68M▼ 28.9% | -21.74M▲ 0% |
| FCF Margin % | -4367.69% | -14895.36% | -264293.33% | -1246.8% | -166.9% | -36.29% | -1025.7% | -242.06% | -1542.97% | -652.96% |
| FCF Growth % | -63% | -126.26% | -54.29% | 65.83% | 51.37% | 18.54% | -26.81% | -46.29% | -28.94% | -10.89% |
| FCF per Share | -25.98 | -30.45 | -38.70 | -10.65 | -4.25 | -2.69 | -3.39 | -4.83 | -5.22 | -5.22 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.87x | 0.96x | 0.88x | 0.72x | -28.55x | 0.41x | 0.56x | 0.72x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 524K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLSD Key Ratios
Clearside Biomedical, Inc. (CLSD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -147.9% | -126.73% | -367.79% | -176.96% | -182.83% | 1.61% | -135.63% | - | - | 55.47% |
| Return on Invested Capital (ROIC) | -42.54% | -135.58% | -271.94% | -221.49% | - | -56.32% | -801.69% | - | - | 53.08% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 84.63% | 95.68% | 91.05% | 85.55% |
| Net Margin | -4977.31% | -17094.2% | -276060% | -1416.01% | -230.68% | 1.27% | -2482.82% | -394.91% | -2064.42% | -780.9% |
| Debt / Equity | 0.11x | 0.37x | 0.42x | 0.57x | 0.23x | 0.02x | 3.32x | - | - | -0.01x |
| Interest Coverage | - | - | - | -29.31x | -53.54x | - | -9.07x | -2.65x | -2.95x | -1.39x |
| FCF Conversion | 0.88x | 0.87x | 0.96x | 0.88x | 0.72x | -28.55x | 0.41x | 0.56x | 0.72x | 0.84x |
| Revenue Growth | - | -33.65% | -91.3% | 7143.33% | 263.28% | 274.65% | -95.51% | 519.89% | -79.77% | -56.78% |
CLSD Frequently Asked Questions
Clearside Biomedical, Inc. (CLSD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue for fiscal year 2024.
Clearside Biomedical, Inc. (CLSD) saw revenue decline by 79.8% over the past year.
Clearside Biomedical, Inc. (CLSD) reported a net loss of $26.0M for fiscal year 2024.
Dividend & Returns
Clearside Biomedical, Inc. (CLSD) had negative free cash flow of $21.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More CLSD
Clearside Biomedical, Inc. (CLSD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates